Skip to main content

Table 1 Baseline characteristics

From: Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial

  Citrate (n = 66) Heparin (n = 73) P-value
Age, years 67 (36 to 87) 67 (23 to 85) 0.51
Male sex 44 (67) 49 (67) 1.00
Weight, kg 85 (50 to 180) 80 (40 to 220) 0.54
Reason for admission to ICU    0.02
Respiratory failure 23 (35) 45 (62)  
Circulatory failure 18 (27) 10 (14)  
Trauma 2 (3) 2 (3)  
Post-CPR 4 (6) 1 (1)  
Postoperative 19 (29) 15 (21)  
Cause of acute kidney injury    0.64
Sepsis 27 (41) 27 (37)  
Ischaemic 33 (50) 37 (51)  
Other 6 (10) 9 (13)  
At start of CVVH:    
APACHE II 23 (11 to 53) 25 (6 to 43) 0.10
SOFA 10 (2 to 19) 11 (3 to 18) 0.45
SOFA, day 3 9 (2 to 20) 9 (1 to 16) 0.82
Mechanical ventilation 45 (81) 55 (81) 1.00
Vasopressor dependency 41 (75) 54 (79) 0.53
Length of stay in ICU, days 2 (0 to 30) 2 (0 to 25) 0.37
Creatinine, μmol/L 326 (54 to 704) 325 (56 to 845) 0.66
Urea, mmol/L 20.1 (3.3 to 54) 23.6 (4 to 64) 0.38
Potassium, mmol/L 4.6 (2.4 to 8.8) 4.6 (2.9 to 6.5) 0.83
Diuresis in 24 h prior to CVVH, mL 360 (0 to 3,975) 421 (0 to 2745) 0.65
Prescribed dose, mL/kg/h 21 (8 to 32) 23 (7 to 35) 0.18
  1. Median (range) or number (percentage) where appropriate. CVVH, continuous venovenous haemofiltration; CPR, cardiopulmonary resuscitation; APACHE-II, acute physiology and chronic health evaluation score; SOFA, sequential organ failure assessment.